slot fortune gems jili games

slot fortune gems jili games CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full Year 2024 Business Highlights and Subsequent Developments Achieved U.S. Food and Drug Administration (FDA) approval of LYMPHIRTM (denileukin diftitox-cxdl), an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL); Began trading on the Nasdaq exchange under the ticker symbol CTOR on August 13, 2024 , following completion of the merger of Citius Pharma's oncology subsidiary with TenX Keane to form Citius Oncology, Inc., a standalone publicly traded company; Advanced manufacturing, marketing and sales activities in preparation for commercial launch of LYMPHIR in the first half of 2025; key activities included: Manufactured initial inventory for launch and finalized supply chain agreements, Initiated recruitment of targeted field force with contract sales organization, Launched a marketing awareness campaign and engaged with all leading CTCL prescribers, Applied for a unique J-code within the Healthcare Common Procedure Coding System (HCPCS) to facilitate accurate reimbursement, Secured inclusion of LYMPHIR in the National Comprehensive Cancer Network (NCCN) guidelines, critical to clinical decision-making in oncology and hematology, influencing treatment practices and payor reimbursement in the U.S., and Initiated development of the patient support center to help patients access LYMPHIR expeditiously; Supported two investigator-initiated trials to explore LYMPHIR's potential as an immuno-oncology combination therapy being conducted at the University of Pittsburgh Medical Center and the University of Minnesota ; and, Shared interim trial results with the clinical community at the Society for Immunotherapy of Cancer Conference (SITC) of University of Pittsburgh Medical Center's Phase I trial of LYMPHIR with checkpoint inhibitor pembrolizumab. The combination of these two immunomodulatory agents showed clinical benefit in relapsed or refractory gynecological neoplasms, resulting in: 27% objective response rate and 33% clinical benefit rate with median progression free survival of 57 weeks (range: 30-96 weeks), and A manageable safety profile whereby the regimen was well-tolerated with reversible treatment emergent adverse events and no definitive immune-related adverse events greater than or equal to grade 3 documented. Financial Highlights R&D expenses were $4.9 million for the full year ended September 30, 2024 , compared to $4.2 million for the full year ended September 30, 2023 ; G&A expenses were $8.1 million for the full year ended September 30, 2024 , compared to $5.9 million for the full year ended September 30, 2023 ; Stock-based compensation expense was $7.5 million for the full year ended September 30, 2024 , compared to $2.0 million for the full year ended September 30, 2023 ; and, Net loss was $21.1 million , or ($0.31) per share for the full year ended September 30, 2024 compared to a net loss of $12.7 million , or ($0.19) per share for the full year ended September 30, 2023 . "Reflecting on 2024, Citius Oncology has achieved pivotal milestones that underscore our commitment to advancing cancer therapeutics," stated Leonard Mazur , Chairman and CEO of Citius Oncology. "The FDA's approval of LYMPHIR for the treatment of cutaneous T-cell lymphoma marks a significant advancement in providing new options for patients battling this challenging disease. It is the only targeted systemic therapy approved for CTCL patients since 2018 and the only therapy with a mechanism of action that targets the IL-2 receptor. Additionally, the successful merger forming Citius Oncology, now trading on Nasdaq under the ticker CTOR, strengthens our position in the oncology sector. We expect it to facilitate greater access to capital to fund LYMPHIR's launch and the Company's future growth. With a Phase I investigator-initiated clinical trial combining LYMPHIR with pembrolizumab demonstrating promising preliminary results, indicating potential for enhanced treatment efficacy in recurrent solid tumors, and preliminary results expected from a second investigator trial with CAR-T therapies in 2025, we remain excited about the potential of LYMPHIR as a combination immunotherapy." "These accomplishments reflect the dedication of our team and the trust of our investors. As we look ahead, we remain steadfast in our mission to develop innovative therapies that improve the lives of cancer patients worldwide," added Mazur. FULL YEAR 2024 FINANCIAL RESULTS: Research and Development (R&D) Expenses R&D expenses were $4.9 million for the full year ended September 30, 2024 , compared to $4.2 million for the full year ended September 30, 2023 . The increase reflects development activities completed for the resubmission of the Biologics License Application of LYMPHIR in January 2024 , which were associated with the complete response letter remediation. General and Administrative (G&A) Expenses G&A expenses were $8.1 million for the full year ended September 30, 2024 , compared to $5.9 million for the full year ended September 30, 2023 . The increase was primarily due to costs associated with pre-commercial and commercial launch activities of LYMPHIR including market research, marketing, distribution and drug product reimbursement from health plans and payers. Stock-based Compensation Expense For the full year ended September 30, 2024 , stock-based compensation expense was $7.5 million as compared to $2.0 million for the prior year. The primary reason for the $5.5 million increase was due to the amounts being realized over 12 months in the year ended September 30, 2024 , as compared to three months post-plan adoption in the year ended September 30, 2023 . Net loss Net loss was $21.1 million , or ($0.31) per share for the year ended September 30, 2024 , compared to a net loss of $12.7 million , or ($0.19) per share for the year ended September 30, 2023 . The $8.5 million increase in net loss was primarily due to the increase in our operating expenses. About Citius Oncology, Inc. Citius Oncology specialty is a biopharmaceutical company focused on developing and commercializing novel targeted oncology therapies. In August 2024 , its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million , is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. Citius Oncology is a publicly traded subsidiary of Citius Pharmaceuticals. For more information, please visit www.citiusonc.com Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Oncology are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; risks related to research using our assets but conducted by third parties; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov , including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2024 , filed with the SEC on December 27, 2024 , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allen ir@citiuspharma.com 908-967-6677 x113 Media Contact: STiR-communications Greg Salsburg Greg@STiR-communications.com -- Financial Tables Follow – CITIUS ONCOLOGY, INC. CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2024 AND 2023 2024 2023 Current Assets: Cash and cash equivalents $ 112 $ — Inventory 8,268,766 — Prepaid expenses 2,700,000 7,734,895 Total Current Assets 10,968,878 7,734,895 Other Assets: In-process research and development 73,400,000 40,000,000 Total Other Assets 73,400,000 40,000,000 Total Assets $ 84,368,878 $ 47,734,895 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 3,711,622 $ 1,289,045 License payable 28,400,000 — Accrued expenses — 259,071 Due to related party 588,806 19,499,119 Total Current Liabilities 32,700,429 21,047,235 Deferred tax liability 1,728,000 1,152,000 Note payable to related party 3,800,111 — Total Liabilities 38,228,540 22,199,235 Stockholders' Equity: Preferred stock - $0.0001 par value; 10,000,000 shares authorized: no shares issued and outstanding — — Common stock - $0.0001 par value; 100,000,000; 71,552,402 and 67,500,000 shares issued and outstanding at September 30, 2024 and 2023, respectively 7,155 6,750 Additional paid-in capital 85,411,771 43,658,750 Accumulated deficit (39,278,587) (18,129,840) Total Stockholders' Equity 46,140,339 25,535,660 Total Liabilities and Stockholders' Equity $ 84,368,878 $ 47,734,895 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Revenues $ — $ — Operating Expenses: Research and development 4,925,001 4,240,451 General and administrative 8,148,929 5,915,290 Stock-based compensation – general and administrative 7,498,817 1,965,500 Total Operating Expenses 20,572,747 12,121,241 Loss before Income Taxes (20,572,747) (12,121,241) Income tax expense 576,000 576,000 Net Loss $ (21,148,747) $ (12,697,241) Net Loss Per Share – Basic and Diluted $ (0.31) $ (0.19) Weighted Average Common Shares Outstanding – Basic and Diluted 68,053,607 67,500,000 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Cash Flows From Operating Activities: Net loss $ (21,148,747) $ (12,697,241) Adjustments to reconcile net loss to net cash provided by operating activities: Stock-based compensation expense 7,498,817 1,965,500 Deferred income tax expense 576,000 576,000 Changes in operating assets and liabilities: Inventory (2,133,871) - Prepaid expenses (1,100,000) (5,044,713) Accounts payable 2,422,577 1,196,734 Accrued expenses (259,071) (801,754) Due to related party 14,270,648 14,805,474 Net Cash Provided By Operating Activities 126,353 - Cash Flows From Investing Activities: License payment (5,000,000) - Net Cash Used In Investing Activities (5,000,000) - Cash Flows From Financing Activities: Cash contributed by parent 3,827,944 - Merger, net (2,754,296) - Proceeds from issuance of note payable to related party 3,800,111 - Net Cash Provided By Financing Activities 4,873,759 - Net Change in Cash and Cash Equivalents 112 - Cash and Cash Equivalents – Beginning of Year - - Cash and Cash Equivalents – End of Year $ 112 $ - Supplemental Disclosures of Cash Flow Information and Non-cash Activities: IPR&D Milestones included in License Payable $ 28,400,000 $This partnership brings together Panaya's robust AI-powered Smart Testing platform and Tritusa's rich testing expertise to deliver superior testing outcomes for Australian enterprises HACKENSACK, N.J. , Dec. 2, 2024 /PRNewswire/ -- Panaya , the leader in SaaS-based AI-Powered Smart Testing and Change Intelligence for ERP, CRM, and Enterprise Cloud Applications, announces today a new partnership with Tritusa, an Australian company specializing in SAP Testing and Quality Assurance. This collaboration aims to provide Australian enterprises with enhanced SAP testing capabilities, including Test Automation, to ensure seamless, efficient and risk-free SAP implementations. As businesses in Australia increasingly adopt SAP S/4HANA, the need for robust testing solutions has never been greater. Panaya and Tritusa are combining their strengths to meet this demand. Panaya's cutting-edge AI-powered solutions, paired with Tritusa's comprehensive SAP testing services – including Test Management & Governance, Test Assurance, Functional Testing, Test Automation, and Performance Testing – offer a powerful, 360-degree, suite of solutions for organizations looking to optimize their SAP testing processes. This partnership allows businesses to leverage Tritusa's local expertise and Panaya's innovative technology to improve test quality, test environment readiness, and overall test effectiveness. Organizations can now accelerate their SAP projects with confidence, ensuring high-quality outcomes and minimal disruption to their operations. Shabi Levi , Head of Global Channels and Alliances at Panaya , shared his appreciation for the collaboration: "We are very pleased to partner with Tritusa to bring our AI-driven testing solutions to the Australian market. Tritusa's deep understanding of SAP testing and their commitment to quality make them an ideal partner. Together, we will empower Australian businesses to achieve faster, more reliable SAP transformations." Jag Sothivel, Technical Director at Tritusa , also highlighted the value of the partnership: "Partnering with Panaya allows us to offer our clients state-of-the-art testing solutions that go beyond traditional approaches. Panaya's technology perfectly complements our testing services, and we look forward to delivering outstanding results for our customers." About Tritusa Tritusa is an Australian company, specializing in SAP Testing and Quality Assurance. They focus on a comprehensive array of SAP Testing & Assurance services, including Test Management & Governance, Test Assurance, Functional Testing, Test Automation and Performance Testing & Engineering. They go beyond traditional SAP testing approaches and assist their customers to improve their test data quality, test environment quality, and test user quality, ensuring seamless testing outcomes. About Panaya Panaya, a SaaS-based company certified by SAP, Oracle, and Salesforce.com, offers an all-in-one platform for Smart Testing solutions and Change Intelligence tailored for ERP, CRM, and cloud business applications. Panaya accelerates and de-risks digital landscapes with AI-powered Test Automation, Test Management, and Impact Analysis. Panaya's focus on ease of use and an intuitive interface ensures seamless collaboration between business and IT, empowering business users and IT professionals to gain real-time visibility and control over their projects. This capability enables faster releases and continuous delivery of high-quality software. Since its founding in 2006, over 3,000 companies across 62 countries, including a third of the Fortune 500, have trusted Panaya to drive rapid, quality testing and change management in their enterprise business applications. For more information, contact Panaya at marketing@panaya.com or visit www.panaya.com . For media inquiries, contact Dana Averbouch, daverbouch@panaya.com . Logo - https://mma.prnewswire.com/media/1636386/3844879/panaya_Logo.jpg

Not long after Donald J. Trump had secured a second go at being president, a group of dreamers set their sights on building a new world, far from this polluted planet and its troubles. This cohort was not destined for Mars, but to a space within themselves – a digital utopia just for the like-minded. Bluesky is a microblogging site for idealists, devoted to protecting them against the raging reality of divergent opinion in a democratic system. The pilgrims took with them their in-house journal, The Guardian , which left Elon Musk’s X with the flounce of a friendless man leaving a party to which he hadn’t been invited. Henceforth, the trust-funded worldwide webzine will dedicate itself to nurturing the delicate biosphere of an alternative reality. Defectors from Elon Musk’s X are taking up with Bluesky. Credit: NurPhoto via Getty Images Three million users have joined Bluesky over the past week, according to the platform, and they have been busy tending to their new world. In this environment, misinformation and disinformation are not alone the enemy; malinformation – information that does not accord with the idealists’ worldview – is the apple from the tree of knowledge, from which the Devil bid Eve to sup. Curious interlopers from the Other Place – the increasingly uncensored X – have experimented by pushing the boundaries of the sayable on Bluesky. To their delight , reasonably mainstream opinions attract the ire of the moderators, and are soft-censored as “intolerance”. Posts labelled thus are not visible in the app until a user clicks on “show”. This functionality is a clue to what the spotless mind can experience on Bluesky. Only the opposite of malinformation – “euinformation”, eu being the obverse prefix – is welcome here. Euinformation is well-meaning information; not really information so much as a curation of comforting progressive axioms. Meanwhile, in the real world, way over here in Australia, I’m never quite sure which way the discussion is going to go when someone raises the re-election of Donald Trump. Given space to speak, tradies volunteer that it’s not a surprise to them that Trump won. Hairdressers venture that it might be a good thing. Even in trendy urban enclaves, the anti-Trump clucking is not as secure as in 2016. Loading The top three concerns in the US election were democracy (presumably whether it would be honoured), the economy and migration. But the cultural effect of focusing on those essentials is wide-reaching. On reflection, it seems everyone knew that they or other people privately had less and less patience with the vanity projects of the boardroom, while the economy constricted the lives of salary men and women. Acronyms have been crumbling. Many companies have slunk away from the ESG (environmental, social and governance) trend as it has emerged that many were just faking it. Australian companies have become more wary about the claims they make in this area after corporate watchdog ASIC announced it was cracking down on greenwashing – the “practice of misrepresenting the extent to which a financial product or investment strategy is environmentally friendly, sustainable or ethical”. In August this year, the world’s largest investment firm, BlackRock , which has $US10 trillion ($15.4 trillion) under management, reported that it had dramatically reduced its support for shareholder proposals addressing environmental and social issues. Another acronym, DEI (diversity, equity and inclusion), is also under fire. Over 200 US colleges have backtracked on their DEI programs, as suggestions swirl that race-based admissions programs have disadvantaged some ethnic groups, including Asian Americans. The grandmama of corporate DEI, White Fragility author Robin DiAngelo, was accused of appropriating passages and ideas in her PhD dissertation from minority scholars without attribution. DiAngelo has become wealthy lecturing corporate teams around the Anglosphere on DEI, leaving them with a tangle of rules and terminology so confusing that their main use is to be weaponised in internal disputes. DEI scepticism and exhaustion have reached Australia too, with some consultants reporting that companies are scaling back, or at the very least rebranding, these departments.

The concept of senior living is changing—it is no longer confined to retirement and care. The new era envisions vibrant ecosystems where seniors—either young by age or young at heart—can live, connect, and thrive. This shift can be partly attributed to how ageing is perceived. Today's Seniors focus on healthy ageing, an active lifestyle, and staying connected and purposeful. They seek opportunities to remain involved in society by participating in social gatherings that promote vitality and youthfulness, such as fitness activities or day clubbing events. Aiming to stray away from passive roles, they look for spaces where they can continue to contribute meaningfully, engage socially, and maintain a sense of autonomy. The Dynamics Of Senior Living Such a mindset rejects the traditional view of ageing as a time of retreat and diminishment. Globally, this paradigm shift in senior living reflects changing societal needs and economic potential. For instance, in Germany, the ageing baby boomer generation seeks communities that enhance their quality of life while embracing health, activity, and belonging. However, the country's senior housing offering must enable a community-based and active lifestyle for young seniors. On the other hand, countries like Sweden and Japan create inclusive, active living environments for seniors. Sweden focuses on mixed-use communities that foster intergenerational interaction. Meanwhile, Japan incorporates high-tech solutions like robotics and home care innovations that foster local senior communities. Communities have a significant role to play in this context. They must emphasise inclusivity and interaction to ensure seniors feel they belong to something larger than themselves through age-specific and intergenerational activities. . YOOBELONG: Changing Our Concept Of Senior Living YOOBELONG is Germany's first local community builder for "young seniors." It offers various housing options, including new builds and converted... Alex RiversKane’s hat-trick sends Bayern 8 points clearWASHINGTON — The Commerce Department's efforts to curb China's and Russia's access to American-made advanced computer chips have been “inadequate” and will need more funding to stymie their ability to manufacture advanced weapons, according to a report published Wednesday by the Senate's Permanent Subcommittee on Investigations. The Biden administration imposed export controls to limit the ability of China and Russia ability to access U.S.-made chips after Russia's invasion of Ukraine nearly three years ago. The agency's Bureau of Industry and Security, according to the report, does not have the resources to enforce export controls and has been too reliant on U.S. chip makers voluntarily complying with the rules. But the push for bolstering Commerce's export control enforcement comes as the incoming Trump administration says it is looking to dramatically reduce the size and scope of federal government. President-elect Donald Trump has tapped entrepreneurs Elon Musk and Vivek Ramaswamy to lead a new “Department of Government Efficiency” to dismantle parts of the federal government. The Trump transition team did not immediately respond to a request for comment on the report. BIS’s budget, about $191 million, has remained essentially flat since 2010 when adjusted for inflation. “While BIS’ budget has been stagnant for a decade, the bureau works diligently around the clock to meet its mission and safeguard U.S. national security,” Commerce Department spokesperson Charlie Andrews said in a statement in response to the report. Andrews added that with “necessary resources from Congress” the agency would be "better equipped to address the challenges that come with our evolving national security environment.” In a letter to Commerce Secretary Gina Raimondo on Wednesday, Democratic Sen. Richard Blumenthal of Connecticut, chair of the subcommittee, pointed to news reports of the Russian military continuing to acquire components from Texas Instruments through front companies in Hong Kong to illustrate how the export controls are failing as an effective tool. Texas Instruments did not immediately respond to a request for comment. “While Congress must provide BIS more resources to undertake its critical mission, it is long past time for BIS to make full use of the enforcement powers Congress has conferred upon it and take aggressive steps to cut the flow of U.S. semiconductors into the Russian war machine,” Blumenthal wrote. Blumenthal in a separate statement added that he was calling on "Commerce to take immediate action and crack down on the companies allowing U.S.-made semiconductors to power Russian weapons and Chinese ambition.” It's not just Texas Instruments that's the issue. The subcommittee in September published a report that found aggregated exports from four major U.S. advanced chip manufacturers nearly doubled from 2021 to 2022 to Armenia and Georgia. Both of those countries are home to front companies known to assist Russia in acquiring advanced chips made in the U.S. despite export controls. China, meanwhile, has created “vast, barely disguised smuggling networks which enable it to continue to harness U.S. technology,” the subcommittee report asserts. Washington has been gradually expanding the number of companies affected by such export controls in China, as President Joe Biden’s administration has encouraged an expansion of investments in and manufacturing of chips in the U.S. But Chinese companies have found ways to evade export controls in part because of a lack of China subject matter experts and Chinese speakers assigned to Commerce's export control enforcement. The agency's current budget limits the number of international end-use checks, or physical verification overseas of distributors or companies receiving American-made chips that are the supposed end users of products. Currently, Commerce has only 11 export control officers spread around the globe to conduct such checks. The committee made several recommendations in its report, including Congress allocating more money for hiring additional personnel to enforce export controls, imposing larger fines on companies that violate controls and requiring periodic reviews of advanced chip companies’ export control plans by outside entities. Boak reported from West Palm Beach, Florida. This article was generated from an automated news agency feed without modifications to text.

The US ethanol market is expected to sustain growth in 2025, coming off a year of record output and exports as the industry seeks support from the incoming Trump administration. According to the US Energy Information Administration, ethanol production averaged 1.051 million b/d through the week ended on Dec. 13, up 2.57% compared to 2023; while weekly output reached a record-high of 1.119 million b/d during the week ended on Nov. 22. In the first quarter of 2024, outright spot ethanol prices reached three-year lows across the physical markets, according to Platts, part of S&P Global Commodity Insights, assessments. Softer spot prices have continued for most of the year, as the Platts Chicago ethanol benchmark has averaged 24.18% lower in 2024 compared to the previous year through Dec. 20. Despite lower outright prices, ethanol producers maintained favorable margins for the majority of 2024 for back-to-back calendar years. According to Platts, ethanol cash margins averaged 24.30 cents/gal through Dec. 20, compared to 40.88 cents/gal in 2023. Higher ethanol prices are forecast in 2025; however, driven by an increase in demand along with strengthening corn prices, according to S&P Global Commodity Insights analysts. According to Commodity Insights, the Chicago ethanol benchmark is forecasted to average 211 cents/gal in 2025, up from an average of 169 cents/gal in 2024. Additionally, the D4 and D6 Renewable Identification Numbers complex is expected to rise in the coming year with the expected transition from the Blender’s Tax Credit to the Clean Fuel Production Credit, while concerns have risen regarding supply tightness for waste feedstocks including used cooking oil and tallow due to possible import restrictions and tariffs. In previous years, emergency waivers have been granted to allow E15 sales during the summer months, but the ethanol industry continues to seek a permanent solution. “It would be beneficial to have [a permanent rule] in place and not rely on emergency waivers,” a producer said. “This would allow for a more strategic approach.” A provision to allow the year-round sale of E15 was stripped from a congressional funding bill that included close to $31 billion in aid for farmers, on Dec. 21. In an earlier proposed bill, nationwide year-round E15 was included, but the provision has since been removed. As it currently stands, year-round E15 will only be available in eight Midwestern states as per the US Environmental Protection Agency’s final rule in February that granted these states permission to lift the previously in-place summertime ban starting in April 2025. In October, California Governor Gavin Newsome directed the state’s Air Resources Board, or CARB, to expedite the approval of E15. Currently, California is the only US state without access to E15 in entirety. According to Commodity Insights’ short-term outlook, refiner and blender net ethanol inputs are projected to grow to 933,000 b/d in 2025. Through the week ended on Dec. 13, net ethanol inputs have averaged 895,560 b/d in 2024 according to the EIA. Meanwhile, Commodity Insights forecasts US Midwest corn to average $4.18/bushel in 2025, up from the $4.10/bu season-average corn price received by producers in 2024, according to the US Department of Agriculture. In its latest World Agriculture Supply and Demand Estimate report released on Dec. 10, the USDA lowered the marketing year 2024-25 corn ending stocks to 1.938 billion bushels, a decrease of 61 million bushels, or 3.05%, from previous estimates. Meanwhile, corn production for MY 2024-25 was revised to 15.143 billion bushels, down 60 million bushels from previous estimates. Industry participants continue to await guidance on the CFPC under section 45Z of the Inflation Reduction Act, particularly on whether a modified GREET or CORSIA model will be used to calculate life-cycle greenhouse gas emissions to determine credit qualification. Treasury spokesperson Michael Martinez said in a statement on Dec. 3, “The Treasury anticipates issuing guidance before the end of the [Biden] administration that will enable eligible producers to claim the 45Z credit for 2025.” Looking ahead, the ethanol industry’s continued growth into the 2030s will likely hinge on the adoption of ethanol-to-jet sustainable aviation fuel. To meet this goal, ethanol producers will have to lower the carbon intensity of their products to meet greenhouse gas reduction requirements of at least 50%, which will only be viable via significant investments into carbon sequestration and climate smart agriculture practices. Looking back at a record-year for ethanol exports As production levels reached new heights in the US in 2024, a surge in exports helped ease the domestic balance sheet as global ethanol trade dynamics along with cheap US ethanol has favored US product as an import option over competitors, mainly Brazil. Through September, US ethanol exports have totaled 33.142 million barrels, up 33.35% compared to the same period in 2023, according to the latest monthly EIA data released on Nov. 29. Additionally, ethanol exports through the first nine months of the year surpassed the previous record by 11.04%, set in 2018 when exports were reported at 29.848 million barrels through September. For 2025, Commodity Insights forecasts show that US ethanol exports are projected to decrease to an average of 95,000 b/d, down from an average of 119,500 b/d through Dec. 13 according to the EIA. A trader source said that particularly strong exports provided significant margin support throughout 2024, drawing from domestic inventories and keeping supply and demand dynamics mostly balanced amid record levels of production. Brazil, the second largest exporter of ethanol, has seen a shift in drivers’ preference for hydrous E100 at retail pumps since late 2023, which has led to a spike in domestic ethanol demand and a decrease in product leaving the country, opening the door for increased US ethanol exports to fill overseas demand. The US has seen large volumetric increases in ethanol outflows to major destinations including the UK, India, and Colombia. According to UNICA, the Brazilian Sugarcane Industry Association, Brazilian ethanol exports have totaled 1.785 million cu m, or 11.234 million barrels, through November, down 19.42% compared to the same period in 2023. Meanwhile, through October domestic retail ethanol sales have increased 41% compared to the same period in 2023, according to Brazil’s National Petroleum Agency. Source: Reuters

MANCHESTER, England : New Manchester United's manager Ruben Amorim is known for an ability to connect with players that many say his predecessor Erik ten Hag did not possess, but the 39-year-old thinks he can be stern when he needs to be. The Portuguese cut a charismatic figure in his first press conference as United head coach on Friday, and his warm rapport especially with the nine journalists who travelled from Portugal only added to his reputation for genuine likeability. But asked if he also has a ruthless side that might be needed to restore a team languishing 13th in the Premier League table ahead of Sunday's match at Ipswich Town to former glory, the former Sporting manager said it was possible to be both. "You can be the same person. There are some places to have fun. There are some places to work hard. So I can be ruthless when I have to be," Amorim said. "If you think as a team, I will be the nicest guy that you have ever seen. If there is someone just thinking for himself, I will be a different person. And I'm not like that kind of guy that wants to show that he's the boss. "They will feel it in the small details that I can be the smiling one, but then, when you have to job to do, I will be a different person, and they understand that." Amorim, known as the "poet" by Portugal and former United forward Cristiano Ronaldo for his communication skills, also erased concerns raised by British media about his English with his thoughtful answers on Friday. He stumbled only once, over the word "suspicious". Because of the international break, Amorim had only two training sessions with his squad before they take the pitch at Portman Road on Sunday ahead of a gruelling stretch of games. It is not how he would have planned his early days with his new team. "It's so much harder to come to a team in the middle of the season, because you have to get to know the players during the games," Amorim said. "(But) it depends. If you are winning, it's a lot of fun having a lot of games, trying to make some changes tactically and winning games. But if you are losing, you don't have the time in training to work out everything you want to work." Following the clash with 17th-placed Ipswich, they host Bodo/Glimt in Amorim's first game at Old Trafford, and entertain Everton in the league. The three matches are part of a packed schedule of 12 games in six weeks. "Where you can improve a team is in training. This is the most important aspect... it is really hard to do it on video or in recovering trainings," Amorim said. "But we will find ways to try to cope with that."Georgetown head coach Ed Cooley is in the headlines this Saturday for reasons that have nothing to do with his team's 82-65 win over Saint Francis. Speaking to reporters this Saturday afternoon, Cooley raved about Georgetown guard Jayden Epps. The talented junior had 23 points, six rebounds and three steals against Saint Francis. Instead of just complimenting Epps for becoming a two-way player, Cooley took a dig at the guard's former school. "His development defensively is almost like he's a new player. It’s something I saw in him his freshman year when he played for that other [expletive] school," Cooley told reporters . "I'm pretty sure that'll make national news when I say that, but I never said the school it was." Obviously, Cooley was referring to Illinois. That's where Epps started his college career before transferring to Georgetown. He averaged 9.5 points per game in his only season with the Fighting Illini. A few hours after Cooley made this remark, he issued an apology to Illinois. As far as apologies are concerned, it was pretty weak. "My comment today was said in jest with one of my players, but I admit it was a poor choice of words," Cooley said. "I have the utmost respect for the University of Illinois, its men’s basketball program, coaches and players." G Fiume/Getty Images Retracting an initial statement less than two hours after its made is a pretty weak move on Cooley's part. Also, it's tough to say it's a joke when he had a serious tone at Georgetown's press conference. Epps is having a nice season with the Hoyas. So far, he's averaging 15.3 points per game. Next time Cooley thinks about mentioning Epps at a press conference, he may want to refrain from bringing up Illinois. Related: PETA Furious With Geno Auriemma, UConn For Goat Ceremony

WELLINGTON, New Zealand , Dec. 19, 2024 /PRNewswire/ -- WAISL is delighted to announce the launch of its Digital Twin-Powered Integrated Airport Predictive Operations Centre (APOC) at Hyderabad International Airport in India . The avant-garde solution was unveiled by the Honourable Union Minister of Civil Aviation, Ram Mohan Naidu Kinjarapu, who lauded the pioneering efforts of the Chairman and leadership of Rajiv Gandhi International Airport Hyderabad and their technology partners. This is India's first end-to-end fully integrated digital twin-powered APOC that covers the Terminal, Airside and Landside, integrating with over 40 modules and tracking more than 100 KPIs, capable of managing 40+ million passengers annually. WAISL's innovative APOC solution can significantly enhance the efficiency of New Zealand airports, reduce flight delays, and enhance passenger satisfaction. By integrating advanced technologies, the country's airports can effectively manage rising passenger volumes, improve revenue streams, and reduce operational expenditures, ensuring a seamless and efficient travel experience. This deployment ushers in a new era in airport operations, offering predictive, prescriptive, and simulative insights and a comprehensive 360-degree view of the entire airport ecosystem. The solution leverages next-generation technologies like Digital Twin, Cloud Computing, Computer Vision, AI/ML, video, and Data Analytics. WAISL had identified and established a key partnership with Kloudspot using their IoT technology for this solution. More recently, WAISL partnered with AWS to further evolve this solution and take it to other airport and transport clients globally. This was launched by AWS via press releases and at their prestigious Re-invent in Las Vegas a few weeks ago. "At WAISL, we are setting a new benchmark for airports worldwide. We don't just innovate; we transform the boundaries of what's possible. In the digital age, transformative impact stems not from technology alone but from its bold, strategic application to complex operational challenges," said Rishi Mehta , President & CEO of WAISL Ltd. WAISL's digital solution is designed to deliver significant business advantages for airports. It delivers real-time insights and an automated plan of the day that seamlessly integrates with all systems, predicts potential disruptions, analyses trends, and continuously learns from post-operative analysis for performance optimisation. " We want to clear the myth and quantify a real achievable business value and RoI to Airport Operators and CxOs who are in various stages of maturity with their APOC strategy. The WAISL digital APOC is one of the first to embrace Total Airport Management, Con-Ops, and IOT/AI/ML technology to drive end-to-end Digital Operations Transformation. This milestone underscores WAISL's commitment to being a preferred digital transformation and innovation partner for airports and the larger aviation and transport industry worldwide," said Preetham Kamesh , acting Global Chief Business Officer of WAISL Ltd. The business value for airport operations by deploying the solution is derived by enhancing capacity with existing infrastructure, optimising non-aero revenue streams, and lowering costs through improved operational efficiency. The solution empowers airports to handle surges in demand with predictive and prescriptive analytics, ultimately reducing flight delays and enhancing passenger satisfaction. It also provides a truly integrated experience that will fuel the next generation of airport operations, setting a new standard in the New Zealand aviation industry. About WAISL At WAISL, we design, implement and integrate technologies with a focus on operations and process efficiencies for airports, airlines, smart cities, energy and hospitality. Our solutions—spanning biometric systems, digital twins, integrated command and control centres, cyber security/sustainability suites, predictive data-driven insights, etc. — work together seamlessly to deliver more innovative, efficient, and intuitive experiences, elevating business outcomes. WAISL is the primary solutions partner for Indira Gandhi International Airport, Delhi , Rajiv Gandhi International Airport, Hyderabad , Manohar International Airport, Goa , Bhogapuram International Airport, Kannur International Airport, and Kuwait International Airport. We manage and service 135+ million passengers and 80+ airlines, integrating and deploying 2000+ applications vendor-agnostically in highly complex technology-converging ecosystems. This excellence in managed services delivered by WAISL has enabled our partner airports to be rated amongst the best-in-class service providers by Skytrax and ACI awards. Website: https://www.waisl.in Photo 1: https://mma.prnewswire.com/media/2583513/Rishi_Mehta_WAISL.jpg Photo 2: https://mma.prnewswire.com/media/2583514/WAISL_innovative_APOC.jpg

None

Simon Harris said he has apologised to a woman for not giving her enough time to speak about carers and disability services while he was out canvassing in Cork on Friday. The Taoiseach and Fine Gael leader said he spoke to Charlotte Fallon, a worker with St Joseph’s Foundation, on the phone on Saturday after a clip of an exchange between them on Friday went viral. RTE footage posted to the social media site X shows Mr Harris on a canvass in Kanturk when Ms Fallon tells the Taoiseach carers ‘were ignored’ and the Government has ‘done nothing for us’. ‘The disability sector is a joke,’ she says. ‘You’ve done nothing for us, our people are suffering. I’m very passionate about my job.’ Mr Harris responds by saying: ‘No, not at all,’ and: ‘I’m very passionate about disability too.’ Ms Fallon says: ‘But there’s no mention of (them in the) Budget. You ignored them, you ignore the carers,’ to which Mr Harris says: ‘That’s not true,’ several times before shaking her hand and walking away. While out canvassing at a Christmas market in Rathfarnham in Dublin on Saturday afternoon, Mr Harris said he was annoyed with himself and had called Ms Fallon to apologise. ‘I called Charlotte this morning because she was absolutely owed an apology from me,’ he said. ‘We had a very good conversation, a very good conversation. I was very grateful to her for her time and her kindness. Fine Gael leader Simon Harris was approached during a canvass this evening by a woman who says she is a carer, and who said she believes the Government has "done nothing for us" | follow live: https://t.co/eUoCK3Qb5Y pic.twitter.com/MXiN9b60Ke ‘We spoke about a number of issues, we spoke about disability services, we spoke about the issue of pay parity for people in Section 39 organisations, and we also spoke about the issue of the means test for carers. ‘I was grateful to have a chance to listen to Charlotte and also talk through with her some of my own plans and views and vision in relation to disability services. Really grateful for the conversation, learned a lot from it, and I’ve also said that I’d love to call in to where she works in Cork in the coming weeks, and she said I’d be very welcome. ‘I’m annoyed with how I didn’t give that person, Charlotte, the time last night, she deserved that time. A post shared by Simon Harris (@simonharristd) ‘I’ve been around the country and I’ve had hundreds of conversations some days, and I’ve learned a lot and always learned a lot from listening to people and I’m very sorry that didn’t happen last night.’ Asked what happened last night, he said: ‘There’s no excuse for it, I’m annoyed with myself in relation to it, disability is what makes me tick. ‘It will always be my passion, and it’s Charlotte’s passion too, and I’m really grateful to her for giving me the opportunity to speak with her today.’ Asked whether he thought people would doubt his sincerity on wanting to reform the State’s disability services after seeing the video, Mr Harris said: ‘I hope not. ‘All I can do is really double my efforts to convince people of the facts that we have a plan for the future of this country, and very much at the heart of that plan is better services, better delivery and better empowerment of people with disabilities. ‘I’ve tried to bring a focus to it since I’ve become Taoiseach, and it’s something that I will continue to work on intensively and even more intensively as a result of this.’ On Saturday morning, Mr Harris posted a video on Instagram where he said he was spurred on to become a politician after seeing his parents fight for access to services for his brother Adam, who has autism. He said the interaction happened at the end of a ‘very long day’ and he felt ‘really bad’ about it. Mr Harris then outlined his party’s plans for carers and the disability sector, including removing the means testing for the Carers’ Allowance and to ensure that there are therapies in special schools and special classes. Sinn Fein’s housing spokesperson Eoin O Broin said that Mr Harris’ reaction ‘showed the true face of Fine Gael ‘ and showed ‘a contempt for working people’. Speaking at a press event in Dublin on Saturday, Fine Gael ministers Helen McEntee and Paschal Donohoe defended their party leader. ‘I think the Taoiseach himself has been very clear that he wished the encounter had gone differently. It had been the end of a very, very long day,’ Ms McEntee said. ‘What he said very clearly is that he should have given her more time, and should have engaged for longer with her, but this is the reason he got into politics.’ Mr Donohoe said: ‘In the course of an election campaign, in all the interactions that we have with people, of course, we sometimes feel within ourselves ‘that could have gone differently’ and ‘could have gone better’. I think it’s particularly the case for somebody who is so committed to looking at how we can support those who need more.’

The stealth symptoms of killer diseases you might spot in loved ones this ChristmasLove scores 3 TDs, No. 6 Notre Dame hands No. 18 Army 1st loss with 49-14 romp at Yankee Stadium

LeBlanc and Joly offer little details about visit with Trump's team in FloridaBreak Barriers, Build Success: Expert Translation and Marketing Solutions by Chinese Copywriter

More puzzles, less sleep

Allegion PLC stock falls Monday, underperforms market

Cardinals are average through 12 games and the frustration is it feels as if they could be better

Thomas Frank unhappy with officials in game with Brighton

NEW YORK , Dec. 23, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Altair Engineering Inc. (NASDAQ: ALTR)'s sale to Siemens for $113.00 per share in cash. If you are an Altair shareholder, click here to learn more about your legal rights and options . Sandy Spring Bancorp (NASDAQ: SASR)'s sale to Atlantic Union Bankshares Corporation for 0.900 shares of Atlantic Union common stock for each share of Sandy Spring . If you are a Sandy Spring shareholder, click here to learn more about your rights and options . Atlantic Union Bankshares Corporation (NYSE: AUB)'s merger with Sandy Spring Bancorp. If you are an Atlantic shareholder, click here to learn more about your rights and options . Cyclo Therapeutics, Inc. (NASDAQ: CYTH)'s merger with Rafael Holdings, Inc. If you are a Cyclo shareholder, click here to learn more about your rights and options . Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email sadeh@halpersadeh.com or zhalper@halpersadeh.com . Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Halper Sadeh LLC Daniel Sadeh, Esq. Zachary Halper, Esq. (212) 763-0060 sadeh@halpersadeh.com zhalper@halpersadeh.com https://www.halpersadeh.com View original content to download multimedia: https://www.prnewswire.com/news-releases/shareholder-investigation-halper-sadeh-llc-investigates-altr-sasr-aub-cyth-on-behalf-of-shareholders-302338489.html SOURCE Halper Sadeh LLP

If like me you spent decades growing your eyebrows back after overzealously plucking in the ’90s, or listening to your mother’s warnings that you’d end up with a bladder chill or an unwanted pregnancy (or possibly both) from venturing out in hipster jeans, then you too might be bemused to see these trends return. But if younger generations want to revive unflattering bubble skirts and mullets, who are we to stop them? However, we can all agree certain things should be consigned to the history books forever — namely smoking and sexually transmitted diseases. Sadly, both are making a comeback, due in no small part to a current lack of public health campaigns about the dangers of smoking and unsafe sex leading to complacency among young people. But while STDS never have been and never will be cool, smoking is receiving something of an image boost through popular culture and social media. Advertising of tobacco products has been banned for more than three decades but the tobacco industry, which is worth more than $14 billion in Australia and almost $1.5 trillion globally, continues to protect its bottom line and its reach is pervasive. Jay Hanna According to nonprofit health organisation Truth Initiative, streaming TV shows can triple a young person’s odds of starting to vape or smoke. It points out that four of this year’s Emmy-nominated animated shows, including The Simpsons, contained tobacco imagery, while nine out of 10 of the year’s Best Picture Oscar nominees featured smoking, up from seven out of 10 films the year before. While watching Jamie-Lee Curtis take a frantic drag of her fag while mentally unravelling in The Bear won’t encourage anyone to light up, seeing the show’s main star Jeremy Allen White smoking, on and off set, might. Likewise promotional posters for the 2023 thriller Saltburn — featuring topless stars Jacob Elordi and Barry Keoghan — could have been a modern day Marlboro Man advertising campaign. The music industry is not immune either. The album most listened to in 2024, Taylor Swift’s The Tortured Poets Department, references smoking in four songs, while in the music video for Die With a Smile, Lady Gaga sings with a cigarette dangling from her mouth. And Charli XCX, whose album Brat was arguably the most culturally impactful and critically acclaimed release of the year, summed up the ethos behind it as: “a pack of cigs, a Bic lighter and a strappy white top with no bra”. While we all know smoking is dangerous, somehow it has never looked uncool, which is why limiting exposure is important. “I’ve never smoked or vaped but damn a cigarette would look so good with some of my outfits,” a millennial male colleague told me. Another confessed she’d been re-watching Mad Men and had to admit the stars looked incredibly chic as they puffed their way to early graves. Jay Hanna I have never been a smoker but I have also seen first-hand the devastating impact it can have from watching my grandmother struggle to overcome her addiction before it eventually killed her, following a short battle with lung cancer, at 68. I am also of a generation that was bombarded with public health messaging about smoking with horrifying images of cancerous mouths and other body parts forever burnt upon our collective retinas. Smoking, which increases the risk of 16 types of cancer — not to mention stroke, heart disease and diabetes — remains the leading cause of preventable death and disease in Australia. Meanwhile vaping, which can cause poisoning and lung disease, is currently more popular among young people, with the number of secondary students who have vaped more than doubling since 2017. Jonine Jancey, Director at Curtin University’s Centre for Evidence Impact and Research in Public Health, said vaping could “support the re-normalisation of smoking”, pointing to research from the Australian National University which indicated that non-smokers who vape are three times more likely to take up smoking as those who have never vaped. One 20-year-old smoker told me she started vaping at 17 before moving on to cigarettes. “Smoking is much cooler than vaping,” she said, adding that her favourite singers Chappell Roan and Dua Lipa both smoke. “But I will quit when I am older.” Professor Jancey said while she welcomes the Federal Government’s introduction of a national anti-vaping program in schools, a multi-faceted approach is needed, including restricting exposure. “Education is great, but we need to stop the exposure and access to these harmful products,” she said. “Our research shows vaping is widely promoted to young people on social media. These social media companies must ensure the health of their users is prioritised over commercial interests.” Perhaps part of the strategy could involve bombarding social media and streaming shows with images of Gen Xers smoking, because we all know how quickly things become uncool when embraced by older generations. Like when Xers absconded to Instagram the minute Boomer relations started “poking” us on Facebook. After all, if anyone was going to post old photos of us in hipster jeans, it would be them.